Active Ingredient History
Glucose is a sugar with the molecular formula C6H12O6. The D-isomer (D-glucose), also known as dextrose, occurs widely in nature, but the L-isomer (L-glucose) does not. Glucose is made during photosynthesis from water and carbon dioxide, using energy from sunlight. The reverse of the photosynthesis reaction, which releases this energy, is a very important source of power for cellular respiration. Glucose is stored as a polymer, in plants as starch and in animals as glycogen, for times when the organism will need it. Glucose circulates in the blood of animals as blood sugar. Glucose can be obtained by hydrolysis of carbohydrates such as milk, cane sugar, maltose, cellulose, glycogen etc. It is however, manufactured by hydrolysis of cornstarch by steaming and diluting acid. Glucose is the human body's key source of energy, through aerobic respiration, providing about 3.75 kilocalories (16 kilojoules) of food energy per gram. Breakdown of carbohydrates (e.g. starch) yields mono- and disaccharides, most of which is glucose. Use of glucose as an energy source in cells is by either aerobic respiration, anaerobic respiration, or fermentation. All of these processes follow from an earlier metabolic pathway known as glycolysis. The insulin reaction, and other mechanisms, regulate the concentration of glucose in the blood. Glucose supplies almost all the energy for the brain, so its availability influences psychological processes. When glucose is low, psychological processes requiring mental effort (e.g., self-control, effortful decision-making) are impaired. Ingested glucose is absorbed directly into the blood from the intestine and results in a rapid increase in the blood glucose level. Glucose is used to manage hypoglycemia and for intravenous feeding. Nausea may occur after ingesting glucose, but this also may be an effect of the hypoglycemia which is present just prior to ingestion. Other adverse effects include increased blood glucose, injection site leakage of fluid (extravasation), injection site inflammation, and bleeding in the brain. NCATS
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Achilles Tendon (Phase 2/Phase 3)
Acidosis, Lactic (Phase 2/Phase 3)
Acute Kidney Injury (Phase 3)
Acute Pain (Phase 4)
Agammaglobulinemia (Phase 3)
Alcohol Withdrawal Delirium (Phase 2/Phase 3)
Back Pain (Phase 2)
Behcet Syndrome (Phase 4)
Brain Neoplasms (Phase 2)
Bronchiolitis (Phase 3)
Carcinoma, Hepatocellular (Phase 3)
Carnitine (Phase 2/Phase 3)
Common Variable Immunodeficiency (Phase 3)
Deficiency Diseases (Phase 2/Phase 3)
Dehydration (Phase 2)
Depression (Phase 3)
Depressive Disorder, Major (Phase 3)
Diabetes Mellitus (Phase 2)
Diabetes Mellitus, Type 1 (Phase 1)
Diabetes Mellitus, Type 2 (Phase 1)
Diabetic Ketoacidosis (Phase 3)
Enterocolitis, Necrotizing (Phase 2)
Gastroenteritis (Phase 3)
Gastroparesis (Phase 2)
Healthy Volunteers (Phase 1)
Heart Diseases (Phase 3)
Heart Failure (Phase 2)
Hypertension (Phase 4)
Hypertension, Pulmonary (Phase 4)
Hypertrophy, Left Ventricular (Phase 3)
Hyponatremia (Phase 3)
Hypospadias (Phase 2/Phase 3)
Hypotension (Phase 3)
Immunologic Deficiency Syndromes (Phase 3)
Infant, Premature (Phase 3)
Infant, Premature, Diseases (Phase 3)
Insulin Resistance (Phase 2/Phase 3)
Intestinal Neoplasms (Phase 3)
Kidney Failure, Chronic (Phase 4)
Liver Cirrhosis (Phase 2)
Liver Neoplasms (Phase 2)
Lung Diseases (Phase 4)
Magnesium Deficiency (Phase 2/Phase 3)
Metabolic Diseases (Phase 2/Phase 3)
Mycoses (Phase 1)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neurodevelopmental Disorders (Phase 2/Phase 3)
Osteoarthritis, Knee (Phase 2/Phase 3)
Ovarian Neoplasms (Phase 2)
Pelvic Pain (Phase 3)
Postoperative Complications (Phase 4)
Renal Dialysis (Phase 4)
Renal Insufficiency (Phase 1)
Sepsis (Phase 3)
Severe Combined Immunodeficiency (Phase 3)
Shock, Septic (Phase 3)
Tennis Elbow (Phase 4)
Tobacco Use Disorder (Phase 3)
Urinary Tract Infections (Phase 3)
Wernicke Encephalopathy (Phase 2/Phase 3)
Wiskott-Aldrich Syndrome (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
